Kelly Brownell moved these ideas into mainstream obesity research
GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
GLP-1 medications reliably produce weight loss but require ongoing use, and most patients regain about two-thirds of the lost weight within a year of stopping
The ease of once-weekly dosing helps improve treatment adherence and simplifies the management of blood glucose levels for those with type 2 diabetes
Effects on Reward Circuits One of the most intriguing findings is GLP-1s interaction with the brains mesolimbic reward system
